Form 4: TransMedics Group Executive Tamer Khayal Exercises Options and Sells Shares

Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares on November 1, 2024, according to a recent SEC filing.

Summary

• On November 1, 2024, Tamer Khayal, the Chief Commercial Officer of TransMedics Group, Inc., exercised stock options to acquire 1,083 shares of common stock at a price of $13.28 per share.
• Simultaneously, Khayal sold 1,083 shares of common stock at a weighted average price of $82.64, with individual sales ranging from $82.55 to $82.76.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
• Following these transactions, Khayal directly owns 20,843 shares of TransMedics Group, Inc.
• Khayal also holds options to purchase 17,334 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports insider trading activity under a pre-arranged plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates